Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections

July 31, 2024
By Nausheen Ahmed, MD
Commentary
Video

A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.

Infection prevention and management is an area that, if addressed, would improve outcomes in patients receiving CAR T-cell therapy, according to Nausheen Ahmed, MD, lead author of a Blood Advances retrospective study.

CancerNetwork® spoke with Ahmed, an associate professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center. She conveyed that addressing treatment-emergent infections following CAR T-cell therapy is an opportunity that may be resolved by adopting a hybrid model of care between physicians and specialized care facilities.

Ahmed highlighted infections following CAR T-cell therapies were an area where differences could be made in patient outcomes. To address this, she emphasized a hybrid model of patient care, where specialized care facilities worked in conjunction with primary care physicians to help devise strategies to manage the frequency and severity of infections.

The retrospective study reviewed data from 475 patients across 9 centers who received CAR T therapy for relapsed or refractory large B-cell lymphoma from 2018 to 2023. Patients received either axicabtagene ciloleucel (axi-cel; Yescarta; n = 216), tisagenlecleucel (tisa-cel; Kymriah; n = 158), and lisocabtagene maraleucel (liso-cel; Breyanzi; n = 101).

Non-relapse mortality (NRM) was defined as death due to causes unrelated to disease progression and was commonly associated with infectious complications. New-onset CRS and ICANS were portrayed as percentages of patient populations at risk.

Data from the study show new-onset CRS and ICANS, respectively, occurred in 0% and 0.7% of patients with B-cell non-Hodgkin lymphoma (NHL) at 2 weeks following CAR T-cell infusion. Additionally, no new cases of CRS occurred after 2 weeks, with 1 additional incidence of ICANS occurring week 3. Additionally, all-cause and non-relapse mortalities, respectively, occurred in 42.8% and 9.5% of all patients, including 46% and 12% of axi-cel recipients, 48% and 7% of tisa-cel recipients, and 27% and 9% of liso-cel recipients (P = .0011; P = .3150).

Transcript:

The main take home here is that we have a [long way to go] in order to improve outcomes for these patients who are receiving CAR T-cell therapy. Specifically, one of the areas where we can make a difference is infection prevention and management. [Considering] the way things have been divided into such blocks of time [before patients] go to the referring physician, there may be a gap in that transition. There has to be more of a hybrid model of care.

There has to be more involvement of our referring doctors or community doctors in detecting and managing these infections or working with the specialized center in order to bypass the [emergency room] with other strategies to help these patients. That's going to be important. If there are enough data to say that the patients do not need extra restrictions beyond 2 weeks, which is what our studies show, then reconsidering the requirements will be one step towards decreasing disparities in access [to CAR T-cell therapy]. There are many other things that can be done at many other levels. This will be one of the things that I will be looking forward to seeing [progress].

Reference

Ahmed N, Wesson W, Lutfi F, et al. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Advances. Published online July 24, 2024. doi:10.1182/bloodadvances.2023012549

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Related Content

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.


A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.


FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

Tim Cortese
May 6th 2025
Article

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Related Content

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.


A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.


FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

Tim Cortese
May 6th 2025
Article

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.